A considerable proportion of autoantibody-negative children with type 1 diabetes mellitus actually have monogenic forms of diabetes mellitus, which enables tailored treatment. Thus, a diagnosis of monogenic diabetes mellitus should be considered and genetically tested for in this group of patients, even if the clinical criteria for monogenic diabetes mellitus are not met.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parviainen, A., But, A., Siljander, H., Knip, M. & Finnish Pediatric Register. Decreased incidence of type 1 diabetes in young Finnish children. Diabetes Care 43, 2953–2958 (2020).
Harsunen, M. T. et al. Identification of monogenic variants in more than ten per cent of children without type 1 diabetes-related autoantibodies at diagnosis in the Finnish Pediatric Diabetes Register. Diabetologia https://doi.org/10.1007/s00125-022-05834-y (2022).
Carlsson, A. et al. Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish national cohort study. Diabetes Care 43, 82–89 (2020).
Sumnik, Z. et al. Five years of improving diabetes control in Czech children after the establishment of the population-based childhood diabetes register ČENDA. Pediatr. Diabetes 21, 77–87 (2020).
Colclough, K., Ellard, S., Hattersley, A. & Patel, K. Syndromic monogenic diabetes genes should be tested in patients with a clinical suspicion of maturity-onset diabetes of the young. Diabetes 71, 530–537 (2022).
Stankute, I. et al. Systematic genetic study of youth with diabetes in a single country reveals the prevalence of diabetes subtypes, novel candidate genes, and response to precision therapy. Diabetes 69, 1065–1071 (2020).
Mirshahi, U. et al. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts. Am. J. Hum. Genet. 109, 2018–2028 (2022).
Pöllänen, P. M. et al. Autoantibodies to N-terminally truncated GAD65(96-585): HLA associations and predictive value for type 1 diabetes. J. Clin. Endocrinol. Metab. 107, e935–946 (2022).
Food and Drug Administration. FDA approves first drug that can delay onset of type 1 diabetes. FDA.gov https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes (2022).
Chiarelli, F., Rewers, M. & Phillip, M. Screening of islet autoantibodies for children in the general population: a position statement endorsed by the European Society for Paediatric Endocrinology. Horm. Res. Paediatr. 95, 393–396 (2022).
Acknowledgements
The authors acknowledge support from Ministry of Health of the Czech Republic (NV18-01-00078).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Pruhova, S., Dusatkova, P. Monogenic diabetes mellitus hidden in autoantibody-negative diabetes mellitus. Nat Rev Endocrinol 19, 132–133 (2023). https://doi.org/10.1038/s41574-022-00800-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-022-00800-5
